Navigation Links
The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers
Date:6/9/2009

SAN MARINO, Calif., June 9 /PRNewswire/ -- Epeius Biotechnologies' Rexin-G is the world's smallest hero (www.epeiusbiotech.com). Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high concentrations within the flagrant, otherwise intractable tumors with one goal in mind: to destroy the metastatic cancers from the inside. Guided by nature's own disease-seeking factors (i.e., pathotropic targeting), armed with a powerful tumor-killing designer gene, and trained in the art of efficient gene delivery over aeons of evolutionary engineering, these tiny therapeutic particles represent a new paradigm in drug delivery and a new class of anti-cancer agents that exhibit profound and unprecedented single-agent efficacy in many cancers.

By selectively targeting cancers and their associated blood supply, while sparing normal cells and healthy tissues, these tiny nano-particles are inherently "smart." In performing a vital cancer surveillance function, they are uniformly "vigilant." By taking on a broad spectrum of cancers that are determined to be refractory to standard chemotherapy (i.e., ineffectual apothecary), they are exceedingly "valiant." By reducing the cancer patient's body burden and extending overall survival, they are truly "heroic." In a manner of speaking, these tiny nano-particles may well be the smallest heroes in all the world.

These "heroic" qualities are now embodied in the tumor-targeted anti-cancer agent, Rexin-G, developed by Epeius Biotechnologies. Rexin-G is currently approved for the treatment of all solid chemo-resistant tumors in the Republic of the Philippines. It has recently been granted Orphan Drug Status and market protections for three separate cancer indications by the U.S. FDA. Ongoing clinical trials in the U.S. have established the thresholds for bioactivity and the dose-dependent efficacy of Rexin-G, as well as its overall safety and lack of any dose-limiting toxicity. Recent advanced and confirmatory clinical trials in the U.S. have demonstrated single-agent efficacy, which included both progression-free survival and overall survival. Not bad, for the world's smallest unsung hero.

For further information about Rexin-G, high-performance targeting technologies, and/or new products in development, see www.epeiusbiotech.com. For further information about current clinical trials, contact Erlinda M. Gordon, M.D., at egordon@epeiusbiotech.com.

*(LOGO: Send2Press.com/mediaboom/09-0418-Epeius_72dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tickets for Brand New Exhibition Body Worlds & The Mirror of Time on Sale 18 July
2. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
3. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. Signostics Receives FDA Clearance for Worlds Smallest Ultrasound Product
6. Stanford writes in worlds smallest letters
7. Smallest ever quantum dots bring real world applications closer
8. Detecting smallest contaminations on semiconductors with aid of synchrotron radiation
9. Naviscans PEM Flex(TM) Detects Smallest Cancers Better Compared to MRI in an Independent Study
10. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
11. Graphene used to create worlds smallest transistor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. ... to perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... healthcare and technology sector at their fourth annual Conference where founders, investors, innovative ... speakers and the ELEVATE pitch competition showcasing early stage digital health and med ...
(Date:10/5/2017)... ... 05, 2017 , ... LabRoots , the leading provider of educational and ... giving back to cancer research with a month-long promotion supporting the advancement of breast ... shoppers can use promo code PinkRibbon to get 10 percent off their purchase of ...
(Date:10/5/2017)... ... 2017 , ... NIH has awarded Circulomics two SBIR grants ... technology . Nanobind is a novel magnetic disk that contains a high density ... for a wide variety of sample preparation applications. The nanostructured surface provides high ...
Breaking Biology Technology:
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):